A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis

A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis

BackgroundPsoriasis is a chronic inflammatory skin disease. EDP1815 is an oral, gut-restricted preparation of non-live Prevotella histicola, the first of a new immunomodulatory therapeutic class targeting the small intestine to generate systemic anti-inflammatory responses.ObjectiveTo evaluate safet...

Full description

Bibliographic Details
Main Authors: Benjamin D. Ehst, Bruce Strober, Andrew Blauvelt, Douglas Maslin, Debbie Macaro, Nancy Carpenter, Mark Bodmer, Duncan McHale
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-05-01
Series:Frontiers in Medicine
Subjects:
immunomodulation of skin
Prevotella
EDP1815
psoriasis
phase 2 clinical trial
small intestinal mucosa
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2024.1292406/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2024.1292406/full

Similar Items